News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Date	Title
Sep 15, 2021	DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit
Sep 07, 2021	DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference
Jul 29, 2021	DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs
Jul 22, 2021	DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29
Jul 14, 2021	DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
Jun 23, 2021	DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)
Jun 09, 2021	DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)
May 04, 2021	DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs
Apr 27, 2021	DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4
Mar 09, 2021	DURECT Corporation Announces Publication of DUR-928's Mechanism of Action
Mar 04, 2021	DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs
Mar 03, 2021	DURECT Corporation to Participate in Three Investor Conferences in March 2021
Feb 25, 2021	DURECT Corporation to Announce 2020 Financial Results and Provide Business Update on March 4
Feb 04, 2021	DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock
Feb 03, 2021	DURECT Corporation Announces Proposed Offering of Common Stock
Feb 02, 2021	DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Following Arthroscopic Subacromial Decompression
Jan 25, 2021	DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Jan 05, 2021	DURECT Corporation Appoints Two New Board Members
Jan 04, 2021	DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million